Please assess the completion status of the following clinical trial:

Trial Title: A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to comprehend and willingness to sign a written informed consent form.~* Confirmed diagnosis of locally advanced or metastatic SCAC.~* Must have received (or been intolerant to or ineligible for) at least 1 prior line of platinum-based chemotherapy and received no more than 2 prior systemic treatments.~* Must have measurable disease by RECIST v1.1.~* Eastern Cooperative Oncology Group performance status of 0 to 1.~* If HIV-positive, then all of the following criteria must also be met: CD4+ count ≥ 300/μL, undetectable viral load, and receiving highly active antiretroviral therapy.~Exclusion Criteria:~* Receipt of anticancer therapy or participation in another interventional clinical study within 21 days before the first administration of study drug; 6 weeks for mitomycin C.~* Radiotherapy within 14 days of first dose of study treatment with the following caveats: 28 days for pelvic radiotherapy, 6 months for thoracic region radiotherapy that is \> 30 Gy.~* Prior treatment with programmed cell death protein 1 (PD-1) or programmed cell death ligand protein 1 (PD-L1)-directed therapy.~* Active autoimmune disease requiring systemic immunosuppression.~* Known central nervous system (CNS) metastases and/or carcinomatous meningitis.~* Known active hepatitis infection.~* Active infections requiring systemic therapy.~* Is pregnant or breastfeeding or is expecting to conceive or father children within the projected duration of the study, from screening through 6 months after the last dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Retifanlimab 500 mg (Type: EXPERIMENTAL): Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).

Based on this trial design, predict the completion outcome and termination type (if applicable).